PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Drug Discovery: Solving the Structure of an Anti-hypertension Drug Target
July 2015
Retrospective: 7,000 Structures Closer to Understanding Biology
July 2015
Design and Evolution: Bespoke Design of Repeat Proteins
June 2015
Design and Evolution: Tunable Antibody Binders
June 2015
Immunity: Clustering Immunoglobulins
June 2014
Immunity: Conformational Capture
June 2014
Immunity: One Antibody to Rule Them All
June 2014
Immunity: Tissue Contribution
June 2014
Caught in the Act
December 2013
Serum Albumins and Allergies
October 2013
The Immune System: A Brotherhood of Immunoglobulins
June 2013
The Immune System: A Strong Competitor
June 2013
The Immune System: Strand Swapping for T-Cell Inhibition
June 2013
The Immune System: Super Cytokines
June 2013
Tuning Immune Response with Costimulation
June 2013
Regulatory insights
September 2012
Serum albumin diversity
August 2012
Substrate specificity sleuths
April 2012
Buena VISTA
February 2012
Analyzing an allergen
January 2012
TLR4 regulation: heads or tails?
October 2011
Binding complement with complementarity
June 2011

Research Themes Immunology

The Immune System: A Strong Competitor

SBKB [doi:10.1038/sbkb.2012.144]
Featured Article - June 2013
Short description: HLA-DO is an MHCII mimic that prevents the association of HLA-DM to MHCII.

HLA-DM (α, blue; β, cyan) in complex with DO (α, red; β, magenta). The three major DO–DM interfaces are highlighted with yellow ovals. 1

Major histocompatibility class II (MHCII) complexes present peptide antigens to T cells as part of a mechanism that allows immune surveillance of self and foreign antigens and activation of an immune response. Two MHCII-like proteins, HLA-DM and HLA-DO in humans, modulate peptide presentation in the endosomes of antigen-presenting cells. HLA-DM catalyzes the removal of a short peptide called CLIP, a remnant of the protein that escorts the MHCII complex from the endoplasmic reticulum to the endosome. Removal of CLIP allows binding of pathogen- and self-derived peptides to the MHCII binding groove. In addition, HLA-DM also promotes the dissociation of weakly bound peptides, ensuring the accumulation of high-affinity peptides. HLA-DO associates with HLA-DM and inhibits its peptide exchange properties, but the exact mechanism was previously unknown.

Using crystallography, mutagenesis and kinetic studies, Stern and colleagues show that HLA-DO is a substrate mimic that binds HLA-DM and inhibits its interaction with MHCII. The crystal structure of the HLA-DO–HLA-DM complex (PDB 4I0P) shows that HLA-DO has an overall topology very similar to classical MHCII molecules and binds HLA-DM in the same region as MHCII. Mutagenesis and peptide-binding kinetic analysis confirm that HLA-DO engages the same residues as MHCII, but binds with higher affinity.

These findings have important implications for how tolerance to self-antigens is maintained and for peptide repertoire modulation. In fact, HLA-DO-deficient mice have a different spectrum of MHCII-bound peptides than wild-type animals, and this is potentially related to differing cellular localization of HLA-DO and HLA-DM. In the multivesicular body, where MHCII complexes associate with peptides, HLA-DM is present in both the inner and outer membranes, while HLA-DO appears only in the latter. This suggests that MHCII molecules on the inner membrane are free to associate with HLA-DM and are consequently loaded with high-affinity peptides, while MHCII molecules on the outer membrane must scavenge for low-affinity peptides. Therefore, the presence of HLA-DO may promote the surface expression of self-peptides, which are of lower affinity than pathogen-derived peptides, and thus contribute to maintenance of tolerance to self.

Ioana Visan

References

  1. A.I. Guce et al. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.
    Nat. Struct. Mol. Biol. 20, 90-98 (2013). doi:10.1038/nsmb.2460

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health